238 related articles for article (PubMed ID: 28261749)
1. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
Sandberg D; Tolmachev V; Velikyan I; Olofsson H; Wennborg A; Feldwisch J; Carlsson J; Lindman H; Sörensen J
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1337-1346. PubMed ID: 28261749
[TBL] [Abstract][Full Text] [Related]
2. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
[TBL] [Abstract][Full Text] [Related]
3. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
[TBL] [Abstract][Full Text] [Related]
5. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [
Altena R; Burén SA; Blomgren A; Karlsson E; Tzortzakakis A; Brun N; Moein MM; Jussing E; Frejd FY; Bergh J; Tran TA; Hartman J; Axelsson R
J Nucl Med; 2024 May; 65(5):700-707. PubMed ID: 38548353
[TBL] [Abstract][Full Text] [Related]
6. Human Epidermal Growth Factor Receptor 2-Targeting [
Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
[TBL] [Abstract][Full Text] [Related]
7. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer.
Alhuseinalkhudhur A; Lubberink M; Lindman H; Tolmachev V; Frejd FY; Feldwisch J; Velikyan I; Sörensen J
EJNMMI Res; 2020 Mar; 10(1):21. PubMed ID: 32201920
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
Baum RP; Prasad V; Müller D; Schuchardt C; Orlova A; Wennborg A; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jun; 51(6):892-7. PubMed ID: 20484419
[TBL] [Abstract][Full Text] [Related]
11. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
[TBL] [Abstract][Full Text] [Related]
12. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Ulaner GA; Hyman DM; Ross DS; Corben A; Chandarlapaty S; Goldfarb S; McArthur H; Erinjeri JP; Solomon SB; Kolb H; Lyashchenko SK; Lewis JS; Carrasquillo JA
J Nucl Med; 2016 Oct; 57(10):1523-1528. PubMed ID: 27151988
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
14.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
16. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical evaluation of
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
